Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses

Trends in Immunology

Volumn 29, Issue 12, 2008, Pages 624-632

  Feng, Xin ^a   Hui, Kwok Min ^a   Younes, Hashem M ^a   Brickner, Anthony G ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMINO ACID SEQUENCE; CANCER CONTROL; CHEMOTHERAPY; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HISTOCOMPATIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LYMPHOCYTE; PROPHYLAXIS; REVIEW; SOLID TUMOR; T LYMPHOCYTE;

ANIMALS; EPITOPES; GRAFT VS LEUKEMIA EFFECT; GRAFT VS TUMOR EFFECT; HUMANS; IMMUNOTHERAPY; MINOR HISTOCOMPATIBILITY ANTIGENS; NEOPLASMS;

EID: 56249123683     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2008.09.004     Document Type: Review

References (95)

1. Appelbaum F.R. The current status of hematopoietic cell transplantation. Annu. Rev. Med. 54 (2003) 491-512
2. Bleakley M., and Riddell S.R. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat. Rev. Cancer 4 (2004) 371-380
3. Drobyski W.R., et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 82 (1993) 2310-2318
4. Collins Jr. R.H., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15 (1997) 433-444
5. Porter D.L., and Antin J.H. Donor leukocyte infusions in myeloid malignancies: new strategies. Best Pract. Res. Clin. Haematol. 19 (2006) 737-755
6. Gribben J.G. Stem-cell transplantation in chronic lymphocytic leukaemia. Best Pract. Res. Clin. Haematol. 20 (2007) 513-527
7. Molldrem J.J., et al. Overexpressed differentiation antigens as targets of graft-versus-leukemia reactions. Curr. Opin. Hematol. 9 (2002) 503-508
8. Lee P.P., et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5 (1999) 677-685
9. Gattinoni L., et al. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6 (2006) 383-393
10. Kahl C., et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 110 (2007) 2744-2748
11. Barrett A.J., and Savani B.N. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 20 (2006) 1661-1672
12. Demirer T., et al. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nat. Clin. Pract. Oncol. 5 (2008) 256-267
13. Lundqvist A., and Childs R. Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions. J. Immunother. 28 (2005) 281-288
14. Shlomchik W.D. Graft-versus-host disease. Nat. Rev. Immunol. 7 (2007) 340-352
15. Goulmy E. Minor histocompatibility antigens: from transplantation problems to therapy of cancer. Hum. Immunol. 67 (2006) 433-438
16. Schmaltz C., et al. T cells require TRAIL for optimal graft-versus-tumor activity. Nat. Med. 8 (2002) 1433-1437
17. Harty J.T., et al. CD8+ T cell effector mechanisms in resistance to infection. Annu. Rev. Immunol. 18 (2000) 275-308
18. Ferrara J.L. Cellular and cytokine effectors of acute graft versus host disease. Int. J. Hematol. 76 Suppl 1 (2002) 195-198
19. Blazar B.R., et al. CD4+ and CD8+ T cells each can utilize a perforin-dependent pathway to mediate lethal graft-versus-host disease in major histocompatibility complex-disparate recipients. Transplantation 64 (1997) 571-576
20. Khouri I.F., et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98 (2001) 3595-3599
21. Brickner A.G. Mechanisms of minor histocompatibility antigen immunogenicity: the role of infinitesimal versus structurally profound polymorphisms. Immunol. Res. 36 (2006) 33-41
22. Murata M., et al. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J. Exp. Med. 197 (2003) 1279-1289
23. Kawase T., et al. Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen. Blood 110 (2007) 1055-1063
24. Brickner A.G., et al. The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood 107 (2006) 3779-3786
25. de Rijke B., et al. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J. Clin. Invest. 115 (2005) 3506-3516
26. Spierings E., et al. The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. Blood 102 (2003) 621-629
27. Warren E.H., et al. An antigen produced by splicing of noncontiguous peptides in the reverse order. Science 313 (2006) 1444-1447
28. Brickner A.G., et al. The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. J. Exp. Med. 193 (2001) 195-206
29. den Haan J.M., et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 279 (1998) 1054-1057
30. Pierce R.A., et al. The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein. J. Immunol. 167 (2001) 3223-3230
31. Dolstra H., et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J. Exp. Med. 189 (1999) 301-308
32. Slager E.H., et al. Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. Blood 107 (2006) 4954-4960
33. Dolstra H., et al. Bi-directional allelic recognition of the human minor histocompatibility antigen HB-1 by cytotoxic T lymphocytes. Eur. J. Immunol. 32 (2002) 2748-2758
34. Miklos D.B., et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft versus host disease and disease remission. Blood 105 (2004) 2973-2978
35. Zorn E., et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J. Exp. Med. 199 (2004) 1133-1142
36. McCarroll S.A., et al. Common deletion polymorphisms in the human genome. Nat. Genet. 38 (2006) 86-92
37. Redon R., et al. Global variation in copy number in the human genome. Nature 444 (2006) 444-454
38. Mullally A., and Ritz J. Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood 109 (2007) 1355-1362
39. de Bueger M., et al. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J. Immunol. 149 (1992) 1788-1794
40. Warren E.H., et al. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood 91 (1998) 2197-2207
41. Akatsuka Y., et al. Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling. Br. J. Haematol. 123 (2003) 671-675
42. Perez-Garcia A., et al. Minor histocompatibility antigen HA-8 mismatch and clinical outcome after hla-identical sibling donor allogeneic stem cell transplantation. Haematologica 90 (2005) 1723-1724
43. Mutis T., et al. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat. Med. 5 (1999) 839-842
44. Mutis T., et al. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 93 (1999) 2336-2341
45. Bonnet D., et al. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 8639-8644
46. Marijt W.A., et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 2742-2747
47. Kircher B., et al. Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion. Br. J. Haematol. 117 (2002) 935-939
48. Dickinson A.M., et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat. Med. 8 (2002) 410-414
49. Goulmy E., et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N. Engl. J. Med. 334 (1996) 281-285
50. Lin M.T., et al. Absence of statistically significant correlation between disparity for the minor histocompatibility antigen-HA-1 and outcome after allogeneic hematopoietic cell transplantation. Blood 98 (2001) 3172-3173
51. Murata M., et al. No significant association between HA-1 incompatibility and incidence of acute graft-versus-host disease after HLA-identical sibling bone marrow transplantation in Japanese patients. Int. J. Hematol. 72 (2000) 371-375
52. Kircher B., et al. Hematopoietic lineage-restricted minor histocompatibility antigen HA-1 in graft-versus-leukemia activity after donor lymphocyte infusion. J. Immunother. 27 (2004) 156-160
53. Hambach L., et al. Human cytotoxic T lymphocytes specific for a single minor histocompatibility antigen HA-1 are effective against human lymphoblastic leukaemia in NOD/scid mice. Leukemia 20 (2006) 371-374
54. Fontaine P., et al. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat. Med. 7 (2001) 789-794
55. Meunier M.C., et al. T cells targeted against a single minor histocompatibility antigen can cure solid tumors. Nat. Med. 11 (2005) 1222-1229
56. Welniak L.A., et al. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu. Rev. Immunol. 25 (2007) 139-170
57. Zorn E. CD4+CD25+ regulatory T cells in human hematopoietic cell transplantation. Semin. Cancer Biol. 16 (2006) 150-159
58. Edinger M., et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 9 (2003) 1144-1150
59. Hoffmann P., et al. Donor-type CD4+CD25+ regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Exp. Med. 196 (2002) 389-399
60. Anderson B.E., et al. Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease. Blood 104 (2004) 1565-1573
61. van Bergen C.A., et al. Multiple myeloma reactive T cells recognize an activation induced minor histocompatibility antigen encoded by the ATP dependent interferon responsive (ADIR) gene. Blood 109 (2007) 4089-4096
62. Spierings E., et al. Identification of HLA class II-restricted H-Y-specific T-helper epitope evoking CD4+ T-helper cells in H-Y-mismatched transplantation. Lancet 362 (2003) 610-615
63. Ivanov R., et al. Identification of a 40S ribosomal protein S4-derived H-Y epitope able to elicit a lymphoblast-specific cytotoxic T lymphocyte response. Clin. Cancer Res. 11 (2005) 1694-1703
64. Warren E.H., et al. The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. J. Immunol. 164 (2000) 2807-2814
65. Vogt M.H., et al. UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition. Blood 96 (2000) 3126-3132
66. Tykodi S.S., et al. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin. Cancer Res. 10 (2004) 7799-7811
67. Tykodi S.S., et al. C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients. Clin. Cancer Res. 14 (2008) 5260-5269
68. Riddell S.R., et al. Adoptive transfer of allogeneic antigen-specific T cells. Biol. Blood Marrow Transplant. 12 (2006) 9-12
69. Faber L.M., et al. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Blood 86 (1995) 2821-2828
70. Tsukada N., et al. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood 93 (1999) 2738-2747
71. Matte C.C., et al. Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing. Blood 103 (2004) 4353-4361
72. Riker A., et al. Immune selection after antigen-specific immunotherapy of melanoma. Surgery 126 (1999) 112-120
73. Riddell S.R. Engineering antitumor immunity by T-cell adoptive immunotherapy. Hematology 2007 (2007) 250-256
74. Otten H.G., et al. Prevention of acute graft-versus-host-disease by selective depletion of T cells reactive with minor histocompatibility antigens on epithelial cells. Leuk. Lymphoma 40 (2001) 385-391
75. Hartwig U.F., et al. Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity. Biol. Blood Marrow Transplant. 14 (2008) 99-109
76. Heemskerk M.H., et al. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J. Exp. Med. 199 (2004) 885-894
77. Mommaas B., et al. Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer. Haematologica 90 (2005) 1415-1421
78. Slingluff Jr. C.L., et al. Peptide and dendritic cell vaccines. Clin. Cancer Res. 12 (2006) 2342s-2345s
79. Mommaas B., et al. Identification of a novel HLA-B60-restricted T cell epitope of the minor histocompatibility antigen HA-1 locus. J. Immunol. 169 (2002) 3131-3136
80. Torikai H., et al. The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A*0206. Bone Marrow Transplant. 40 (2007) 165-174
81. den Haan J.M., et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 268 (1995) 1476-1480
82. Akatsuka Y., et al. Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. J. Exp. Med. 197 (2003) 1489-1500
83. Torikai H., et al. The human cathepsin H gene encodes two novel minor histocompatibility antigen epitopes restricted by HLA-A*3101 and -A*3303. Br. J. Haematol. 134 (2006) 406-416
84. Griffioen M., et al. Identification of phosphatidylinositol 4-kinase type II +| as HLA class II-restricted target in graft versus leukemia reactivity. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 3837-3842
85. Terakura S., et al. A single minor histocompatibility antigen encoded by UGT2B17 and presented by human leukocyte antigen-A*2902 and -B*4403. Transplantation 83 (2007) 1242-1248
86. Vogt M.H., et al. The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood 99 (2002) 3027-3032
87. Rosinski K.V., et al. DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells. Blood 111 (2008) 4817-4826
88. Pierce R.A., et al. Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. J. Immunol. 163 (1999) 6360-6364
89. Wang W., et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 269 (1995) 1588-1590
90. Meadows L., et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 6 (1997) 273-281
91. Torikai H., et al. A novel HLA-A*3303-restricted minor histocompatibility antigen encoded by an unconventional open reading frame of human TMSB4Y gene. J. Immunol. 173 (2004) 7046-7054
92. Engelhard V.H., et al. Insights into antigen processing gained by direct analysis of the naturally processed class I MHC associated peptide repertoire. Mol. Immunol. 39 (2002) 127-137
93. Warren E.H., et al. Feasibility of using genetic linkage analysis to identify the genes encoding T cell-defined minor histocompatibility antigens. Tissue Antigens 59 (2002) 293-303
94. Schuler M.M., et al. SNEP: SNP-derived epitope prediction program for minor H antigens. Immunogenetics 57 (2005) 816-820
95. Kawase T., et al. Identification of human minor histocompatibility antigens based on genetic association with highly parallel genotyping of pooled DNA. Blood 111 (2008) 3286-3294